DBV Technologies : Dépôt du dossier d’autorisation de Viaskin Peanut aux Etats-Unis
>Dépôt du dossier de BLA auprès de la FDA… - Conformément au timing que nous avions annoncé dans nos précédents papiers, DBV Technologies annonce ce matin le dépôt du dossier de mise sur le marché auprès de la FDA pour Viaskin Peanut, son actif le plus avancé destiné au traitement de l’allergie à l’arachide chez les patients pédiatriques âgés de 4 à 11 ans. Le dossier se base sur les données des études de phase III PEPITES et REALISE ainsi que les données complémentai...DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on immunotherapy. Co.'s therapeutic approach is based on epicutaneous immunotherapy (EPIT), its proprietary method of delivering biologically active compounds to immune systems through intact skin using a platform called Viaskin. Viaskin is an electrostatic patch that offers a self-administered, non-invasive immunotherapy to patients. Once applied on intact skin, Viaskin forms a condensation chamber that hydrates the skin and solubilizes the antigen, allowing it to penetrate the epidermis, where it's captured by Langerhans cells. Co.'s patients include infants and children suffering from severe food allergies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.